Phathom Pharmaceuticals (PHAT) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Phathom Pharmaceuticals, Inc. has made strides in the healthcare market as their drug VOQUEZNA gains immediate inclusion on Express Scripts’ national formularies for commercial plans. This significant development simplifies patient access to VOQUEZNA by allowing it to be prescribed directly after a generic proton pump inhibitor, streamlining treatment options for those in need.
For further insights into PHAT stock, check out TipRanks’ Stock Analysis page.
